Skip to main content
. Author manuscript; available in PMC: 2021 Sep 15.
Published in final edited form as: Clin Cancer Res. 2020 Dec 29;27(6):1604–1611. doi: 10.1158/1078-0432.CCR-20-4084

Figure 3: Tumor response to osimertinib and navitoclax.

Figure 3:

Waterfall plots of best tumor response as measured by percentage reduction in sum of tumor diameters relative to baseline for patients in the (A) dose escalation cohort and (B) expansion cohort treated at the recommended phase 2 dose of osimertinib and navitoclax.